Int J Angiol 2023; 32(01): 048-055
DOI: 10.1055/s-0042-1759818
Original Article

Single-Center Study Evaluating Long-Term Major Adverse Outcomes with the Use of Paclitaxel-Coated Balloons in Treating Infrainguinal Arterial Disease

1   Midwest Cardiovascular Research Foundation, Davenport, Iowa
,
Elizabeth Sharis
1   Midwest Cardiovascular Research Foundation, Davenport, Iowa
,
Gail A Shammas
1   Midwest Cardiovascular Research Foundation, Davenport, Iowa
,
Susan Jones-Miller
1   Midwest Cardiovascular Research Foundation, Davenport, Iowa
› Author Affiliations

Abstract

Paclitaxel drug-coated balloons (DCB) have been shown to reduce target lesion revascularization (TLR) rate, but recently an association between paclitaxel and an increase in mortality at 5-year was reported. We reviewed the 5-year mortality and freedom from TLR rates from a single center among patients that received DCB. Consecutive patients that received DCB from July 8, 2015 to November 27, 2019 with follow-up obtained from medical records and review of official death certificates were reviewed. The primary objective was total mortality and TLR rates with cumulative exposure to paclitaxel-coated balloons. Demographic, angiographic, clinical, and procedural variables were collected. Causes of mortality were classified according to death certificates. Descriptive analysis was performed on all variables. Kruskal–Wallis test was used to compare the total length of DCBs in those who were alive and those who died by the end of study. Kaplan–Meier (KM) was used to plot the freedom from mortality up to 5 years. A total of 91 symptomatic patients received the Lutonix balloon at index to treat femoropopliteal arterial disease and subsequently received either Lutonix or in.PACT during the follow-up phase for additional procedures. Age was 68.4 ± 10.8 years (56.0% males). Critical limb ischemia was present in 20.9%. There was no statistical difference in mortality between the median total number of balloons used among patients who were alive versus those who died (2.5 vs. 3.0, p-value = 0.89). Also, there was no statistical difference in the total length of DCB balloons used between those who were alive and those who died at the end of the study (p-value = 0.39). There were no in-hospital amputation or death. At 5-year follow-up KM freedom from TLR was 78.5%. A total of 13 patients died during follow-up. Of these 10 received only the Lutonix balloon and 3 did receive both Lutonix and In.PACT. The yearly KM freedom from mortality for the Lutonix only cohort were 92.7, 89.1, 85.5, 83.6, and 81.8% at 1, 2, 3, 4, and 5 years, respectively. Freedom from TLR and mortality at 5 years appears to be favorable with the use of DCB, predominantly Lutonix balloon in this cohort. This data needs to be supported prospectively by a larger number of patients.

Disclaimer

This study was supported by a grant from Bard/BD. Dr. Shammas receives educational and research grants from Bard. Other relevant conflict of interest includes research and educational grants from Phillips and Boston Scientific.




Publication History

Article published online:
13 January 2023

© 2023. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 7 (24) e011245 DOI: 10.1161/JAHA.118.011245.
  • 2 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Paraskevopoulos I, Karnabatidis D. Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol 2020; 31 (02) 202-212
  • 3 Center for Devices and Radiological Health, US Food and Drug Administration. Update: treatment of peripheral arterial disease with paclitaxel coated balloons and paclitaxel-eluting stents potentially associated with increased mortality: letter to health care providers. Published 2019 Accessed November 26, 2022, at: https://www.fda.gov/medical-devices/letters-health-care-providers/update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting
  • 4 Center for Devices and Radiological Health, US Food and Drug Administration. FDA Executive Summary: circulatory system devices panel meeting: general issues panel: paclitaxel-coated drug coated balloon and drug eluting stent late mortality panel. Published 2019 Accessed November 26, 2022, at: https://www.fda.gov/media/127698/download
  • 5 Center for Devices and Radiological Health, US Food and Drug Administration. August 7, 2019 update: treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality. Published 2019 Accessed November 26, 2022, at: https://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel
  • 6 Gray WA, Jaff MR, Parikh SA. et al. Mortality assessment of paclitaxel-coated balloons: patient-level meta-analysis of the ILLUMENATE clinical program at 3 years. Circulation 2019; 140 (14) 1145-1155
  • 7 Schneider PA, Varcoe RL, Secemsky E. et al. Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel. J Vasc Surg 2021; 73 (01) 311-322
  • 8 Schneider PA, Laird JR, Doros G. et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol 2019; 73 (20) 2550-2563 DOI: 10.1016/j.jacc.2019.01.013. Mortality Not Correlated with Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon
  • 9 Albrecht T, Schnorr B, Kutschera M, Waliszewski MW. Two-year mortality after angioplasty of the femoro-popliteal artery with uncoated balloons and paclitaxel-coated balloons-a pooled analysis of four randomized controlled multicenter trials. Cardiovasc Intervent Radiol 2019; 42 (07) 949-955
  • 10 Rosenfield K, Jaff MR, White CJ. et al; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 2015; 373 (02) 145-153
  • 11 Ouriel K, Adelman MA, Rosenfield K. et al. Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. JACC Cardiovasc Interv 2019; 12 (24) 2515-2524
  • 12 Rocha-Singh KJ, Duval S, Jaff MR. et al; VIVA Physicians, Inc. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis. Circulation 2020; 141 (23) 1859-1869
  • 13 Böhme T, Noory E, Beschorner U. et al. Evaluation of mortality following paclitaxel drug-coated balloon angioplasty of femoropopliteal lesions in the real world. JACC Cardiovasc Interv 2020; 13 (17) 2052-2061
  • 14 Thieme M, Von Bilderling P, Paetzel C, Karnabatidis D, Perez Delgado J, Lichtenberg M. Lutonix Global SFA Registry Investigators. The 24-month results of the Lutonix global SFA registry: worldwide experience with Lutonix drug-coated balloon. JACC Cardiovasc Interv 2017; 10 (16) 1682-1690